Janumet

sitagliptin / metformin

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Janumet. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Janumet.

: Janumet is a medicine that contains two active substances, sitagliptin and metformin hydrochloride. It is available as tablets (50 mg sitagliptin / 850 mg metformin hydrochloride; and 50 mg sitagliptin / 1,000 mg metformin hydrochloride).

Janumet is used in patients with type-2 diabetes to improve the control of blood glucose (sugar) levels. It is used in addition to diet and exercise in the following ways:

in patients who are not satisfactorily controlled on metformin (an antidiabetes medicine) used on its own;
in patients who are already taking a combination of sitagliptin and metformin as separate tablets;
in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin (other types of antidiabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin.

The medicine can only be obtained with a prescription.

: Janumet is taken twice a day. The strength of tablet to use depends on the dose of the other antidiabetes medicines that the patient was taking before. If Janumet is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).
The maximum dose of sitagliptin is 100 mg a day. Janumet should be taken with food to avoid any stomach problems caused by metformin.

: Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substances in Janumet, sitagliptin and metformin hydrochloride, each have a different mode of action.
Sitagliptin is a dipeptidyl-peptidase-4 (DPP-4) inhibitor. It works by blocking the breakdown of ‘incretin’ hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By increasing the levels of incretin hormones in the blood, sitagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Sitagliptin does not work when the blood glucose is low. Sitagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. Sitagliptin has been authorised in the European Union (EU) as Januvia and Xelevia since 2007, and as Tesavel since 2008. Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut. Metformin has been available in the EU since the 1950s.
As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type-2 diabetes.

: Sitagliptin on its own as Januvia / Xelevia / Tesavel can be used with metformin, and with both metformin and a sulphonylurea, in type-2-diabetes patients. The company presented the results of three studies of Januvia / Xelevia to support the use of Janumet in patients who were not satisfactorily controlled on their existing metformin treatment. Two of the studies looked at sitagliptin as an add-on to metformin: the first compared it with placebo (a dummy treatment) in 701 patients, and the second compared it with glipizide (a sulphonylurea) in 1,172 patients. The third study compared sitagliptin with placebo, when used as an add-on to glimepiride (another sulphonylurea), with or without metformin, in 441 patients.
The results of three further studies were used to support the use of Janumet. The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Janumet with that of metformin or sitagliptin alone. The second included 278 patients who were not satisfactorily controlled on the combination of metformin and rosiglitazone (a PPAR-gamma agonist) and compared the effects of adding sitagliptin or placebo.
The third included 641 patients who were not satisfactorily controlled on a stable dose of insulin, three quarters of whom were also taking metformin. This study also compared the effects of adding sitagliptin or placebo. In all of the studies, the main measure of effectiveness was the change in the levels of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
The company carried out additional studies to show that the active substances in Janumet are absorbed by the body in the same way as the two medicines given separately.

: Janumet was more effective than metformin alone. Adding 100 mg sitagliptin to metformin reduced HbA1c levels by 0.67% (from around 8.0%) after 24 weeks, compared with a fall of 0.02% in the patients adding placebo. The effectiveness of adding sitagliptin to metformin was similar to that of adding glipizide. In the study in which sitagliptin was added to glimepiride and metformin, the levels of HbA1c were reduced by 0.59% after 24 weeks, compared with an increase of 0.30% in the patients adding placebo.
In the first of the three further studies, Janumet was more effective than metformin or sitagliptin alone. In the second, HbA1c levels were reduced by 1.03% after 18 weeks in patients adding sitagliptin to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo. Finally, they were reduced by 0.59% after 24 weeks in patients adding sitagliptin to insulin, compared with a fall of 0.03% in those adding placebo. There was no difference in this effect between the patients also taking metformin and those not taking it.

: The most common side effect with Janumet (seen in between 1 and 10 patients in 100) is nausea (feeling sick). For the full list of all side effects reported with Janumet, see the package leaflet.
Janumet must not be used in people who are hypersensitive (allergic) to sitagliptin, metformin or any of the other ingredients. It must not be used in patients who have diabetic ketoacidosis or precoma (dangerous conditions that can occur in diabetes), problems with the kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack. It must also not be used in patients who consume excessive amounts of alcohol or are alcoholic, or in women who are breast-feeding. For the full list of restrictions, see the package leaflet.

: The CHMP decided that Janumet’s benefits are greater than its risks and recommended that it be given marketing authorisation.

: The European Commission granted a marketing authorisation valid throughout the EU for Janumet on 16 July 2008.
For more information about treatment with Janumet, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

List item

Janumet : EPAR - Summary for the public (PDF/81.49 KB)

First published: 09/12/2009
Last updated: 05/07/2013
- Bulgarian
  (PDF/136.82 KB)
- Czech
  (PDF/133.33 KB)
- Danish
  (PDF/104.06 KB)
- Dutch
  (PDF/83.56 KB)
- Estonian
  (PDF/112.92 KB)
- Finnish
  (PDF/104.29 KB)
- French
  (PDF/106.8 KB)
- German
  (PDF/84.91 KB)
- Greek
  (PDF/136.54 KB)
- Hungarian
  (PDF/103.6 KB)
- Italian
  (PDF/105 KB)
- Latvian
  (PDF/106.67 KB)
- Lithuanian
  (PDF/129.99 KB)
- Maltese
  (PDF/110.73 KB)
- Polish
  (PDF/133.26 KB)
- Portuguese
  (PDF/105.54 KB)
- Romanian
  (PDF/130.16 KB)
- Slovak
  (PDF/131.82 KB)
- Slovenian
  (PDF/122.82 KB)
- Spanish
  (PDF/106.04 KB)
- Swedish
  (PDF/104.04 KB)
List item

Janumet : EPAR - Risk management plan (PDF/3.59 MB)

First published: 18/11/2022

This EPAR was last updated on 18/11/2022

Authorisation details

Product details
Name	Janumet
Agency product number	EMEA/H/C/000861
Active substance	sitagliptin metformin hydrochloride
International non-proprietary name (INN) or common name	sitagliptin metformin
Therapeutic area (MeSH)	Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code	A10BD07

Publication details
Marketing-authorisation holder	Merck Sharp & Dohme B.V.
Revision	29
Date of issue of marketing authorisation valid throughout the European Union	16/07/2008
Contact address	Waarderweg 39 2031 BN Haarlem The Netherlands

Product information

16/09/2021 Janumet - EMEA/H/C/000861 - WS2091

List item

Janumet : EPAR - Product Information (PDF/416.17 KB)

First published: 09/12/2009
Last updated: 12/10/2021
- Bulgarian
  (PDF/401.91 KB)
- Croatian
  (PDF/432.3 KB)
- Czech
  (PDF/448.22 KB)
- Danish
  (PDF/424.36 KB)
- Dutch
  (PDF/446.62 KB)
- Estonian
  (PDF/454.4 KB)
- Finnish
  (PDF/426.74 KB)
- French
  (PDF/464.48 KB)
- German
  (PDF/476.33 KB)
- Greek
  (PDF/414.89 KB)
- Hungarian
  (PDF/473.17 KB)
- Icelandic
  (PDF/422.36 KB)
- Italian
  (PDF/447.71 KB)
- Latvian
  (PDF/365 KB)
- Lithuanian
  (PDF/423.85 KB)
- Maltese
  (PDF/652.6 KB)
- Norwegian
  (PDF/409.73 KB)
- Polish
  (PDF/483.48 KB)
- Portuguese
  (PDF/441.69 KB)
- Romanian
  (PDF/446.93 KB)
- Slovak
  (PDF/449.8 KB)
- Slovenian
  (PDF/424.52 KB)
- Spanish
  (PDF/439.78 KB)
- Swedish
  (PDF/429.87 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Janumet : EPAR - All Authorised presentations (PDF/20.92 KB)

First published: 14/05/2009
Last updated: 27/03/2014
- Bulgarian
  (PDF/43.02 KB)
- Croatian
  (PDF/33.63 KB)
- Czech
  (PDF/24.98 KB)
- Danish
  (PDF/15.63 KB)
- Dutch
  (PDF/17.49 KB)
- Estonian
  (PDF/18.38 KB)
- Finnish
  (PDF/16.88 KB)
- French
  (PDF/16.78 KB)
- German
  (PDF/18.32 KB)
- Greek
  (PDF/60.39 KB)
- Hungarian
  (PDF/34.44 KB)
- Icelandic
  (PDF/18.5 KB)
- Italian
  (PDF/18.71 KB)
- Latvian
  (PDF/38.43 KB)
- Lithuanian
  (PDF/38.24 KB)
- Maltese
  (PDF/35.84 KB)
- Norwegian
  (PDF/12.93 KB)
- Polish
  (PDF/36.12 KB)
- Portuguese
  (PDF/22.2 KB)
- Romanian
  (PDF/34.37 KB)
- Slovak
  (PDF/25.69 KB)
- Slovenian
  (PDF/25.05 KB)
- Spanish
  (PDF/18.02 KB)
- Swedish
  (PDF/18.22 KB)

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

For patients with type 2 diabetes mellitus:

Janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Janumet is indicated as triple combination therapy with a PPAR agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.
Janumet is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

Assessment history

Changes since initial authorisation of medicine

List item

Janumet : EPAR - Procedural steps taken and scientific information after authorisation (PDF/314.71 KB)

First published: 09/12/2009
Last updated: 30/05/2022
List item

Janumet-H-C-PSUSA-00002003-201708 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation (PDF/66.01 KB)

First published: 03/07/2018
Last updated: 03/07/2018
EMA/423583/2018
List item

Janumet-H-C-A31-1432 : EPAR - Assessment Report - Article 31 (PDF/562.45 KB)

Adopted

First published: 06/02/2017
Last updated: 06/02/2017
EMA/867221/2016
List item

Janumet : EPAR - Scientific Conclusion (PDF/32.54 KB)

First published: 06/02/2017
Last updated: 06/02/2017
- Bulgarian
  (PDF/69.5 KB)
- Croatian
  (PDF/62.6 KB)
- Czech
  (PDF/66.59 KB)
- Danish
  (PDF/29.27 KB)
- Dutch
  (PDF/30.09 KB)
- Estonian
  (PDF/28.67 KB)
- Finnish
  (PDF/29.33 KB)
- French
  (PDF/33.77 KB)
- German
  (PDF/31.79 KB)
- Greek
  (PDF/68.71 KB)
- Hungarian
  (PDF/48.06 KB)
- Icelandic
  (PDF/30.33 KB)
- Italian
  (PDF/29.01 KB)
- Latvian
  (PDF/65.13 KB)
- Lithuanian
  (PDF/65.13 KB)
- Maltese
  (PDF/67.26 KB)
- Norwegian
  (PDF/28.2 KB)
- Polish
  (PDF/49.5 KB)
- Portuguese
  (PDF/29.91 KB)
- Romanian
  (PDF/63.84 KB)
- Slovak
  (PDF/51.54 KB)
- Slovenian
  (PDF/60.9 KB)
- Spanish
  (PDF/29.91 KB)
- Swedish
  (PDF/29.93 KB)
List item

Janumet-H-C-861-II-0003 : EPAR - Assessment Report - Variation (PDF/1.35 MB)

Adopted

First published: 05/02/2013
Last updated: 05/02/2013
EMEA/CHMP/205121/2009
List item

Janumet-H-C-861-II-0013 : EPAR - Assessment Report - Variation (PDF/448.66 KB)

Adopted

First published: 09/12/2009
Last updated: 09/12/2009
EMEA/762518/2009
List item

CHMP post-authorisation summary of positive opinion for Janumet of 24 September 2009 (PDF/33.49 KB)

Adopted

First published: 25/09/2009
Last updated: 25/09/2009
EMEA/CHMP/544393/2009
List item

CHMP post-authorisation summary of positive opinion for Janumet of 23 April 2009 (PDF/33.39 KB)

Adopted

First published: 23/04/2009
Last updated: 23/04/2009
EMEA/CHMP/240520/2009

Janumet

Table of contents

Overview

Janumet : EPAR - Summary for the public (PDF/81.49 KB)

Janumet : EPAR - Risk management plan (PDF/3.59 MB)

Authorisation details

Product information

Janumet : EPAR - Product Information (PDF/416.17 KB)

Janumet : EPAR - All Authorised presentations (PDF/20.92 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Janumet : EPAR - Procedural steps taken and scientific information after authorisation (PDF/314.71 KB)

Janumet-H-C-PSUSA-00002003-201708 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation (PDF/66.01 KB)

Janumet-H-C-A31-1432 : EPAR - Assessment Report - Article 31 (PDF/562.45 KB)

Janumet : EPAR - Scientific Conclusion (PDF/32.54 KB)

Janumet-H-C-861-II-0003 : EPAR - Assessment Report - Variation (PDF/1.35 MB)

Janumet-H-C-861-II-0013 : EPAR - Assessment Report - Variation (PDF/448.66 KB)

CHMP post-authorisation summary of positive opinion for Janumet of 24 September 2009 (PDF/33.49 KB)

CHMP post-authorisation summary of positive opinion for Janumet of 23 April 2009 (PDF/33.39 KB)

Initial marketing-authorisation documents

Janumet : EPAR - Public assessment report (PDF/648.74 KB)

CHMP summary of positive opinion for Janumet (PDF/34.97 KB)

News

Related content

How useful was this page?